FOSAMAX

LOE Approaching

alendronate sodium

NDAORALSOLUTION
Approved
Sep 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Clinical Trials (5)

NCT00293813Phase 2Completed

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Started May 2006
247 enrolled
Postmenopausal Osteoporosis
NCT00330460Phase 3Completed

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

Started May 2006
1,189 enrolled
OsteoporosisOsteopenia
NCT00259857Phase 2Completed

Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis

Started Oct 2003
22 enrolled
Osteoporosis
NCT00010439Phase 2Completed

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

Started Sep 2000
10 enrolled
Osteoporosis
NCT00835406Phase 1Completed

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

Started Jun 2000
140 enrolled
Healthy